ELI LILLY AND COMPANY Prepaid Expense and Other Assets, Current
ELI LILLY AND COMPANY (LLY) had Prepaid Expense and Other Assets, Current of $5.25 billion as of 2023-09-30, per its 10-Q filed 2023-11-02.
Discontinued › Notes › and Other Assets
us-gaap:PrepaidExpenseAndOtherAssetsCurrent · last filed 2023-11-02
- 2023-09-30: Prepaid Expense and Other Assets, Current $5.25B.
- 2023-06-30: Prepaid Expense and Other Assets, Current $4.53B.
- 2023-03-31: Prepaid Expense and Other Assets, Current $3.58B.
- 2022-12-31: Prepaid Expense and Other Assets, Current $2.95B.
| Period end | Prepaid Expense and Other Assets, Current |
|---|---|
| 2023-09-30 | $5.25B 10-Q · filed 2023-11-02 |
| 2023-06-30 | $4.53B 10-Q · filed 2023-08-08 |
| 2023-03-31 | $3.58B 10-Q · filed 2023-04-27 |
| 2022-12-31 | $2.95B 10-Q · filed 2023-11-02 |
| 2021-12-31 | $2.53B 10-K · filed 2023-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Akari Therapeutics Plc (AKTX) | $1,527.991B | -47,921.42 | |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |